Chloroform

Chloroform

SCHEMBL537028

CCN(CC)CC.CCO.ClC(Cl)Cl

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Chloroform. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.40
TSHR P16473 1/20 0.40
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
HIF1A Q16665 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chloroform SCHEMBL8348906 0.97 ALDH1A1 (0.38) ALDH1A1TSHRCYP1A2CYP2C9HPGD
Alcohol SCHEMBL28335960 0.90 TSHR (0.38) ALDH1A1TSHRCYP1A2CYP2C9HPGD
Chloroform SCHEMBL83188 0.90 CYP2C9 (0.32) ALDH1A1CYP1A2CYP2C9HPGDMAPK1
Chloroform SCHEMBL378302 0.89 LMNA (0.33)
Chloroform SCHEMBL2007196 0.87 CYP1A2 (0.31) CYP1A2CYP2C9HPGDMAPK1HIF1A
Chloroform SCHEMBL7930106 0.86 LMNA (0.31)
Alcohol SCHEMBL48558 0.86 ALDH1A1 (0.55) ALDH1A1TSHRCYP1A2CYP2C9HPGD
Alcohol SCHEMBL946131 0.83 ALDH1A1 (0.43) ALDH1A1TSHRCYP1A2CYP2C9HPGD
Alcohol SCHEMBL11582714 0.82 ALDH1A1 (0.50) ALDH1A1TSHRCYP1A2CYP2C9HPGD
Alcohol SCHEMBL18837465 0.82 ALDH1A1 (0.50) ALDH1A1TSHRCYP1A2CYP2C9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2414368-B1 HYDROXYTHIENOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS ACHILLION PHARMACEUTICALS INC (US) 2013-11-27 EP disclosed
US-8173636-B2 Hydroxylthienoquinolones and related compounds as anti-infective agents ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-08 US disclosed
CN-102388053-A Hydroxythienoquinolones and related compounds as anti-infective agents ACHILLION PHARMACEUTICALS INC 2012-03-21 CN disclosed
EP-2414368-A2 HYDROXYTHIENOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS Achillion Pharmaceuticals, Inc. (US) 2012-02-08 EP disclosed
US-20100256112-A1 HYDROXYTHIENOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS ACHILLION PHARMACEUTICALS, INC. (US) 2010-10-07 US disclosed
WO-2010115184-A2 HYDROXYTHIENOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS ACHILLION PHARMACEUTICALS, INC. (US) 2010-10-07 WO disclosed
US-6087490-A Dinucleotide and oligonucleotide analogues NOVARTIS AG (CH) 2000-07-11 US disclosed
WO-1997035869-A1 DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES NOVARTIS AG (CH) 1997-10-02 WO disclosed
US-5633264-A Individual stereoisomers of 7-[3-(1-aminoalkyl)-1-pyrrolidinyl]-Quinolones and naphthyridones as antibacterial agents WARNER-LAMBERT COMPANY (US) 1997-05-27 US disclosed
US-5563155-A QUINOLONE ANTIBIOTICS WITH INCREASED EFFICACY, REDUCED SIDE EFFECTS WARNER-LAMBERT COMPANY (US) 1996-10-08 US disclosed
US-5461165-A Individual stereoisomers of intermediates of 7-[3-(1-aminoalkyl)-1-pyrrolidinyl]-quinolones and naphthyridones as antibacterial agents WARNER-LAMBERT COMPANY (US) 1995-10-24 US disclosed
US-5344940-A Bactericides WARNER-LAMBERT COMPANY (US) 1994-09-06 US disclosed
US-5258528-A Bactericides WARNER-LAMBERT COMPANY (US) 1993-11-02 US disclosed
EP-0559774-A1 INDIVIDUAL STEREOISOMERS OF 7- 3-(1-AMINOALKYL)-1-PYRROLIDINYL]-QUINOLONES AND NAPHTHYRIDONES AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 1993-09-15 EP disclosed
US-5118800-A Oligonucleotides possessing a primary amino group in the terminal nucleotide CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1992-06-02 US disclosed
US-5118802-A DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1992-06-02 US disclosed
US-5015733-A Phosphoramidites and oligonucleotides derived therefrom CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1991-05-14 US disclosed
US-4849513-A Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1989-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256112-A1 HYDROXYTHIENOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS RECQL, QTRT2, DHX35 ALDH1A1 2624/4885TSHR 1934/4885CYP1A2 357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.